ダウンロード数: 201
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
20111_04926.pdf | 503.97 kB | Adobe PDF | 見る/開く |
タイトル: | Recent advance in antigen-specific immunotherapy for acute myeloid leukemia. |
著者: | Kadowaki, Norimitsu Kitawaki, Toshio |
著者名の別形: | 門脇, 則光 |
発行日: | 2011 |
出版者: | Hindawi Publishing Corporation |
誌名: | Clinical & developmental immunology |
巻: | 2011 |
論文番号: | 104926 |
抄録: | Relapse after chemotherapy is inevitable in the majority of patients with acute myeloid leukemia (AML). Thus, it is necessary to develop novel therapies that have different antileukemic mechanisms. Recent advances in immunology and identification of promising leukemia-associated antigens open the possibilities for eradicating minimal residual diseases by antigen-specific immunotherapy after chemotherapy. Several methods have been pursued as immunotherapies for AML: peptide vaccines, granulocyte-macrophage colony-stimulating factor-secreting tumor vaccines, dendritic cell vaccines, and adoptive T cell therapy. Whereas immunogenicity and clinical outcomes are improving in these trials, severe adverse events were observed in highly avid engineered T cell therapies, indicating the importance of the balance between effectiveness and side effects in advanced immunotherapy. Such progress in inducing antitumor immune responses, together with strategies to attenuate immunosuppressive factors, will establish immunotherapy as an important armament to combat AML. |
著作権等: | Copyright © 2011 Norimitsu Kadowaki and Toshio Kitawaki. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
URI: | http://hdl.handle.net/2433/152424 |
DOI(出版社版): | 10.1155/2011/104926 |
PubMed ID: | 22028726 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。